Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell vaccine + CMV pp65 RNA-modified
- Development stage
- Unknown
- Lead developer
- Immunomic Therapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal
01
Overview
**autologous dendritic cell vaccine + CMV pp65 RNA-modified** is an investigational, personalized cellular immunotherapy developed by Antwerp University Hospital. It consists of autologous (patient-derived) monocyte-derived dendritic cells that have been genetically modified ex vivo via electroporation with messenger RNA (mRNA) encoding the cytomegalovirus (CMV) pp65 antigen (the 65 kDa lower matrix phosphoprotein, UL83), a major immunodominant CMV protein. Administered intradermally, the vaccine is designed to prime or boost CMV-specific T-cell immunity (both CD4+ helper and CD8+ cytotoxic T-lymphocyte responses) in CMV-seronegative adults prior to kidney transplantation, with the goal of prophylactically protecting them against CMV infection post-transplant. It is being evaluated in a Phase 1 pilot trial (EudraCT 2012-005575-13) in Belgium assessing its safety, feasibility, and immunogenicity.
- Other names
- CMV pp65 mRNA-loaded autologous dendritic cell vaccineCMV pp65 mRNA-electroporated dendritic cell vaccineautologous CMV pp65-loaded dendritic cell vaccine
02
Targets
MHC I (MHC class I})LAMP1 (Lysosomal-associated membrane protein 1)Cytomegalovirus pp65 peptide-MHC complex
Beyond the preview
Go deeper on autologous dendritic cell vaccine + CMV pp65 RNA-modified.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell vaccine + CMV pp65 RNA-modified.